Integer Holdings (ITGR) witnessed strong momentum year to date. Shares of the company have gained 23.6% compared with 7.5% growth of the industry in the same time frame. The S&P 500 Composite has risen 10.8% during the same period. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Plano, TX-based Integer Holdings manufactures and develops medical devices and components primarily for original equi ...

Integer Holdings Corporation (ITGR) has been gaining from its research and product development activities. The optimism led by a solid first-quarter 2024 performance and its solid foothold in the broader MedTech space are expected to contribute further. However, volatility in energy markets and dependence on third-party suppliers are a hurdle. In the past year, this Zacks Rank #3 (Hold) stock has gained 46% compared with the 6.9% rise of the industry and the S&P 500’s 26.5% growth. The renowned medical devi ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.14 in the first quarter of 2024, which improved 31% year over year. The figure topped the Zacks Consensus Estimate by 1.8%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was 59 cents, reflecting an improvement of 51.3% year over year. Revenues in Detail Integer Holdings registered revenues of $414 ...

财务数据和关键指标变化 - 第一季度销售额同比增长10%,达到4.15亿美元 [16] - 调整后营业利润同比增长26%,增速是销售增速的2.7倍 [17] - 调整后每股收益同比增长31% [18] - 毛利率同比扩大120个基点,主要得益于制造卓越计划的执行以及供应链和直接人工环境的改善 [9] 各条业务线数据和关键指标变化 - 心血管和血管业务(C&V)销售额同比增长18%,所有CMB市场均实现双位数增长 [19] - 心脏起搏管理和神经调节(CRM&N)业务销售额同比增长12%,其中心脏起搏管理和神经调节均实现双位数增长 [19] 各个市场数据和关键指标变化 - 公司没有具体披露各个市场的数据和关键指标变化 [无] 公司战略和发展方向以及行业竞争 - 公司的2017年制定的战略正在产生持续的高于市场的销售增长和利润率扩张 [11] - 公司继续通过收购整合差异化能力,并保持在2.5-3.5倍调整后EBITDA的债务杠杆范围内 [12] - 公司有一个强大的新产品管线,集中在增长更快的终端市场 [12] 管理层对经营环境和未来前景的评论 - 公司对2024年9%-11%的销售增长和13%-20%的调整后营业利润增长保持信心 [9][27][29] - 公司预计2024年上半年销售同比增长高个位数,下半年将持续增长,得益于新产品推出和新兴PMA客户的增长 [31] - 公司预计2024年调整后营业利润率将随着制造效率的持续改善和销售增长超过运营成本增长而不断扩大 [31] 问答环节重要的提问和回答 问题1 **Brett Fishbin 提问** 客户是否存在调整库存的情况,对公司销售造成影响 [39][40][41] **Joe Dziedzic 回答** 公司有900多万美元的订单量,对未来需求有很好的可见性,已将客户调整库存的影响纳入指引 [40][41] 问题2 **Matthew O'Brien 提问** 公司在心电生理学业务的表现和未来预期 [53][54][55][56][57][60][61] **Joe Dziedzic 回答** 公司在心电生理学业务拥有广泛的能力,从部件到成品设备都有涉及,能为客户提供全面支持,预计该业务将持续强劲增长 [54][55][56][57][60][61] 问题3 **Craig Bijou 提问** 公司在心电生理学业务中部件和成品设备的占比,以及未来的变化趋势 [64][65][66][67] **Joe Dziedzic 回答** 目前公司主要业务集中在部件和子装配,未来会努力提高在客户设备上的占比,为客户提供更多的一站式服务 [65][66][67]

Integer (ITGR) reported $414.81 million in revenue for the quarter ended March 2024, representing a year-over- year increase of 9.5%. EPS of $1.14 for the same period compares to $0.87 a year ago. The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $413.29 million. With the consensus EPS estimate being $1.12, the EPS surprise was +1.79%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Integer (ITGR) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 1.79%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.34 per share when it actually produced earnings of $1.39, delivering a surprise of 3.73%. Over the last four ...

销售业绩 - 2024年第一季度销售额增长10%，达到4.15亿美元，有机增长6%[2] - 公司在2024年第一季度实现销售额为41.48亿美元，较去年同期增长9.5%[36] 财务表现 - GAAP净收入增加700万美元，达到2100万美元，增长57%；非GAAP调整后净收入增加1000万美元，达到3900万美元，增长33%[3] - GAAP营业收入增加500万美元，达到3900万美元，增长15%；非GAAP调整后营业收入增加1300万美元，达到6300万美元，增长26%[4] - 净利润为2.05亿美元，较去年同期增长57.1%[37] - 公司在2024年第一季度的毛利为1.1亿美元，较去年同期增长13.7%[36] - 营运费用为7.06亿美元，较去年同期增长12.9%[37] 财务状况 - 负债总额从2023年底增加1.81亿美元，达到11.41亿美元，净负债增加1.62亿美元，达到11.12亿美元[6] - 现金及现金等价物为4.22亿美元，较去年同期增长78.1%[36] - 公司在2024年第一季度的净现金流为2.32亿美元[38] 业务拓展 - 心脏血管销售额增长16%，心脏节律管理和神经调控销售额增长8%，高级外科、骨科和便携医疗销售额增长4%[8][9] 展望与规划 - 2024年展望：销售额预计为17.7亿美元，营业收入预计为2.02亿至2.2亿美元，调整后EBITDA预计为3.55亿美元[11] 资金运作 - 公司在2024年第一季度的投资活动中，主要进行了2.91亿美元的固定资产购置和1.39亿美元的收购[38] - 公司在2024年第一季度的融资活动中，主要进行了1.92亿美元的发行可转债和1.92亿美元的循环信贷融资[38] 会计及财务策略 - 公司在财报电话会议中提到，收购所涉及的会计要求公司按公允价值记录库存，有时高于先前的库存账面价值[48] - 公司在非GAAP财务指标中排除了库存增值摊销，因为他们认为这是一个非现金费用，不代表公司持续经营结果[48] - 公司在调整后的运营收入中包括了无形资产摊销、重组和相关费用、收购和整合成本等[51] - 公司在调整后的EBITDA中包括了股权补偿、重组和相关费用、收购和整合成本等[52] - 公司在调整后的EBITDA中排除了重组和相关费用中包含的金额[52] - 公司在财报电话会议中提到，销售增长已经调整，排除了外汇汇率波动和收购和战略退出的影响[53] - 公司在调整后的净总债务中包括了债务折扣和延期发行成本，减去了现金及现金等价物[54]

Shares of Integer (ITGR) have been strong performers lately, with the stock up 4.6% over the past month. The stock hit a new 52-week high of $120 in the previous session. Integer has gained 19.8% since the start of the year compared to the 0.2% move for the Zacks Medical sector and the 3.9% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the ...

Shares of Integer Holdings Corporation (ITGR) scaled a new 52-week high of $119 on Apr 9, before closing the session marginally lower at $118.99. Over the past year, this Zacks Rank #3 (Hold) stock has gained 50.4% compared with a 9.2% rise of the industry and 27.4% growth of the S&P 500 Composite. Over the past five years, the company registered earnings growth of 4.4% compared with the industry’s 10% rise. The company’s long-term expected growth rate of 15% compares with the industry’s growth projection o ...

Integer Holdings Corporation (ITGR) has been gaining from its research and product development activities. The optimism led by a solid fourth-quarter 2023 performance and its solid foothold in the broader MedTech space are expected to contribute further. However, volatility in energy markets and dependence on third-party suppliers are a hurdle. In the past year, this Zacks Rank #3 (Hold) stock has gained 49.9% compared with the 8.5% rise of the industry and the S&P 500’s 27.2% growth. The renowned medical d ...